This article has Open Peer Review reports available.
Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia
© Jarnjak-Jankovic et al; licensee BioMed Central Ltd. 2005
Received: 21 October 2004
Accepted: 18 February 2005
Published: 18 February 2005
Leukemia is a clonal disorder characterized by uncontrolled proliferation of haematopoietic cells, and represents the most common form of cancer in children. Advances in therapy for childhood leukemia have relied increasingly on the use of high-dose chemotherapy often combined with stem-cell transplantation. Despite a high success rate and intensification of therapy, children still suffer from relapse and progressive disease resistant to further therapy. Thus, novel forms of therapy are required.
This study focuses on dendritic cell (DC) vaccination of childhood leukemia and evaluates the in vitro efficacy of different strategies for antigen loading of professional antigen-presenting cells. We have compared DCs either loaded with apoptotic leukemia cells or transfected with mRNA from the same leukemia cell line, Jurkat E6, for their capacity to induce specific CD4+ and CD8+ T-cell responses. Monocyte-derived DCs from healthy donors were loaded with tumor antigen, matured and co-cultured with autologous T cells. After one week, T-cell responses against antigen-loaded DCs were measured by enzyme-linked immunosorbent spot (ELISPOT) assay.
DCs loaded with apoptotic Jurkat E6 cells or transfected with Jurkat E6-cell mRNA were both able to elicit specific T-cell responses in vitro. IFNγ-secreting T cells were observed in both the CD4+ and CD8+ subsets.
The results indicate that loading of DCs with apoptotic leukemia cells or transfection with tumour mRNA represent promising strategies for development of cancer vaccines for treatment of childhood leukemia.
Leukemia represents the most common form of cancer in children. There are two main types of childhood leukemia, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The success rate in treatment of childhood leukemia has improved continuously over the past decades , and today disease-free survival is 70%–80% for ALL and 40%–60% for AML [2–4]. In the Nordic countries the overall event-free survival in ALL has risen from 57% to75% . However, in children with high-risk ALL, the progress has only been modest. The relapse rate has decreased in parallel with the improving results, but the prognosis after relapse has not improved. Only 25%–30% of children who relapse will reach and remain in a second remission. Children with AML have a worse prognosis than those with ALL. Event-free survival for AML is below 55%, whereas the cure rate for children with ALL is near 80%. The complete remission rate differs also, with 5%–10% induction failures due to refractory disease and toxicity in AML, compared to 1%–2% in ALL .
Immunotherapy based on vaccination with dendritic cells (DCs) has emerged as an attractive new form of therapy for cancer in general, and DC-based vaccines have already shown promise in follicular non-Hodgkin's lymphoma, and in other hematological malignancies [5–7]. DCs are antigen-presenting cells (APCs) specialized to induce T-cell responses against cells exposing foreign peptides, including tumour-related antigens, in context of MHC molecules [8, 9]. DCs reside in tissues in an immature form, where they capture antigens from the environment. After antigen capture, and in response to inflammatory stimuli, DCs mature and migrate to lymph nodes to initiate immunity . Maturation of DCs is associated with up regulation of the co-stimulatory molecules CD80 and CD86, increased expression of HLA molecules, enhancement of their APC function, and expression of CCR7 chemokine receptors that promote migration to the T-cell area in lymph nodes . In several animal studies, it has been shown that immunization with cancer-antigen loaded DCs efficiently primes both CD4+ and CD8+ T-cells, resulting in protective immunity against tumours [11–16].
Vaccination with tumor antigen-loaded DCs has been shown to induce both Th and CTL responses, and tumor regression in some patients [16, 17]. An important issue in optimizing DC vaccines is the choice of tumour antigen for loading of DCs. Several clinical trials in patients with melanoma have demonstrated that vaccination against a single antigen can induce tumour specific CTLs . However, for many tumours no specific cancer antigens are known. For such patients, autologous tumor cells or tumor cell lines containing a repertoire of antigens overlapping with the repertoire in the patient's tumor, represents an alternative source of antigens. Effective cross-priming with antigens from tumour cells has been demonstrated with apoptotic cancer cells [19–21]. Transfer of whole tumor mRNA into DCs represents an alternative way of loading DCs. The transfected mRNA can be expressed for a relatively long period of time [22–24] and give rise to specific T-cell responses in vitro and following vaccination of patients . So far, no studies on the relative efficacy of these two antigen loading methods have been performed. The aim of the present study was to compare DCs either loaded with apoptotic Jurkat E6 cells or transfected with mRNA isolated from Jurkat E6 cells, for their ability to generate T-cell responses against antigens derived from the human T-cell line. The Jurkat leukaemic T-cell line is a reference cell line , and was chosen as a source of antigen in the model experiments described here. We demonstrate that both strategies can be successfully employed to induce T helper and CTL responses against antigens derived from allogeneic leukemic T-cells.
Cytokines and chemicals
GM-CSF was purchased from Novartis (Basel, Switzerland), IL-4, TNFα, IL1β and IL-6 from CellGenix (Freiburg, Germany), and Prostaglandin E2 (PgE2), IL-7, IL-2 and IL-12 from R&D Systems (Minneapolis, USA). Staurosporin was obtained from (Sigma Aldrich, Saint Louise, Missouri).
Preparation of DCs and T cells
PBMC from healthy donors (obtained from Buskerud Hospital, Drammen, Norway) were obtained by density gradient centrifugation (Lymphoprep, Nycomed, Norway). Monocyte-derived DCs were generated under serum-free conditions from the adherent fraction of PBMCs cultured in six-well plates at a density of 4 × 106 cells/ml for 1.5 h at 37°C in 3 ml CellGro DC medium (CellGenix, Freiburg, Germany). Non-adherent cells were collected and frozen for later use as responder cells. Adherent cells were cultured in 3 ml CellGro DC medium, supplemented with 800 U/ml GM-CSF and 10 ng/ml IL-4 every second day, until day 5 when maturation of DCs was induced by addition of maturation cocktail (10 ng/ml TNF- , 10 ng/ml IL-1 1000 U/ml IL-6 and 1 μg/ml PgE2) for 24 h. Characterization of DC phenotype was done by staining 0,5 × 106 cells with fluorochrome-labelled antibodies against the Lin1 panel (CD3, CD14, CD19, CD16, CD20, CD56), HLA-DR, CD1a, CD80, CD83, and CD86 (Becton Dickinson, San Jose, CA), and analyzing by FACSCalibur flow cytometry (Becton Dickinson). The mAb isotypes used were IgG1 FITC, IgG2a PE, IgG1 APC (Becton Dickinson, San Jose, CA).
Assessments of apoptosis and phagocytosis of apoptotic cells
Jurkat E6 cells obtained from American Type Culture Collection (ATCC) were exposed to 1 μM staurosporin for 3 h to induce apoptosis. Apoptotic cell death was assessed using Annexin V-FLUOS as described by the manufacturer (Boehringer Manheim, Manheim, Germany). For assessments of phagocytosis, Jurkat E6 cells were stained with the green fluorescent dye PKH-67 (Sigma Aldrich) as described in the kit manual, exposed to 1 μM staurosporin for 3 h and incubated with immature DCs at a ratio of 3:1. After 6 h, immature DCs were labelled with a red fluorescent antibody (mAb CD1a-PE). Phagocytosis of apoptotic cells was measured quantitatively by flow cytometry. Similarly, phagocytosis was visualized by confocal laser microscopy (Leica TCS SP, equipped with HeNe and Ar lasers) using apoptotic Jurkat E6 cells pre-stained with PKH-26 red fluorescent dye (Sigma Aldrich) and DCs stained with the green fluorescent dye PKH-67.
Preparation of Jurkat E6-cell mRNA and transfection of DCs
Jurkat E6 cells were used as a source of tumor material. Total RNA was isolated from 20–25 × 106 cells using Trizol Reagent as described by the manufacturer (Invitrogen, Basel, Switzerland). Poly (A)+ mRNA was isolated from total RNA using the GenoPrep Direct mRNA kit (GenoVision, Oslo, Norway). Purified mRNA was used fresh or stored at -80°C until use. Transfection of DCs with mRNA was performed as described previously , with minor modifications. Briefly, immature DCs were washed once, resuspended in RPMI-1640 (BIO-Whittaker, Walkersville, MD) and placed on ice. 400 μl (approx. 2 × 106 cells) were mixed with mRNA, transferred to a 4-mm-gap cuvette and pulsed with a BTX ECM-830 square-wave electroporator (Genetronics Inc., San Diego, CA) using instrument settings 500 V and 1 ms. Transfected cells were incubated on ice for 30 s followed by addition of 2.0 ml cold CellGro DC medium supplemented with 10 ng/ml IL-4, 800 U/ml GM-CSF and maturation cocktail (see above), and transferred to standard culturing conditions. Transfection with EGFP-pCIpA102 mRNA (10 μg/400 μl) encoding the green fluorescence protein  was used to verify transfection efficiency.
Isolation of T-cell subsets CD4 and CD8
The Negative Isolation Kit (Dynal, Biotech) was used for isolation of CD4 and CD8 T cells according to the manufacturer's protocol. Isolation was performed on day 7 after in vitro priming, before setting up the ELISPOT assay.
Induction of primary T-cell responses
Mature DCs (0.3 × 106) expressing Jurkat E6-cell mRNA or loaded with apoptotic Jurkat E6 cells, were co-cultured with 3 × 106 autologous non-adherent PBMC for 7 days in 1.0 ml CellGro DC medium without serum, before setting up the ELISPOT assay. The cultures were tested for INF- production in an ELISPOT assay  following restimulation for 24 h with thawed antigen-loaded DC using 0.5 × 105, 1.0 × 105, 2.0 × 105 and 4.0 × 105 responding cells and 0.5 × 104 DCs per well. Mock transfected DCs were used as control. The assay was done in duplicate. Spots were counted manually, and the frequency of reactive T cells was calculated according to the formula: (spots with transfected DC - spots with non transfected DC)/number of T cells added.
Generation of immature DCs and phagocytosis of apoptotic Jurkat E6 cells
Flow cytometry was used to further determine the efficiency of DC loading with apoptotic leukemic cells. In these experiments, apoptotic Jurkat E6 cells had been pre-stained with the green fluorescent dye PKH-67 and DCs were identified by staining with PE-conjugated anti-CD1a. Highly efficient uptake of apoptotic Jurkat E6 cells was confirmed, since virtually all CD1a positive cells showed green PKH-67 staining (Fig. 3a).
Following antigen loading, DCs were matured in the presence of pro-inflammatory cytokines for 24 h. Assessments by flow cytometry confirmed that this treatment led to up-regulation of CD83, and the co-stimulatory molecules CD80 and CD86, in compliance with a mature DC phenotype (Fig. 1b).
Transfection of immature DC with mRNA from Jurkat E6 cells
Analysis of T-cell responses
Immunotherapy for childhood leukemia has the potential to contribute to long-term control or cure of the disease. Until now immunotherapeutic approaches for leukemia have been limited to trials of cytokine therapy . Further development of biologically based treatments may prove to be effective in therapy of patients suffering from this disease. Several forms of DC-mediated immunotherapy are currently being investigated using a wide variety of vaccination protocols summarized in . Two very important issues are the choice of antigen and the method of antigen loading. In the present study we have chosen to use the complex antigen mixture represented by whole tumor cells. Reports comparing the ability of apoptotic and necrotic cells to induce DC maturation  found that incubation of DCs with necrotic, but not apoptotic, tumor cell lines induce maturation. However, other reports concluded that incubation with apoptotic cells is sufficient to induce DC maturation [30–34]. In our study we have used apoptotic cells, and the requirement for DC maturation signals was provided by a standardized maturation cocktail. We accordingly analyzed human monocyte-derived DCs for their ability to: (a) take up apoptotic leukemia cells and express transfected mRNA, (b) express a mature phenotype following tumour-antigen capture and culture in maturation cocktail and (c) prime un-fractionated T cells as well as the CD4+ and CD8+ T-cell subsets. Due to the complexity of the antigens represented by the allogeneic tumor cells, the aim of these model experiments was not to use this allogeneic system to prove that we could elicit tumour specific T-cell responses in this way, but to provide data to demonstrate efficient antigen transfer and compare the relative efficacy of DCs loaded by the two different procedures, in eliciting complex T-cell responses. Our results demonstrate that immature DCs can efficiently take up apoptotic Jurkat E6 cells, and that phagocytosis was mainly confined to the CD1a+ subset of immature DC. Furthermore, support for expression of transfected mRNA derived from the allogeneic leukemia cell line is indirectly provided by its ability to prime T-cell responses specific for transfected cells. We also show that the two different methods of antigen-loading did not result in any apparent differences in the phenotype of the mature DCs. In terms of immune responses both methods of antigen loading produced DCs capable of inducing INF- secreting T cells. However, it appeared that DCs loaded with tumour-mRNA in general were most potent in inducing T-cell responses.
We observed that the frequencies of induced INF-γ producing T cells depended on the individual donor, the method of antigen-loading and the subset of T cells studied. Such variations are not surprising, since the model system used employs allogeneic cells and no effort was done to HLA match the blood donors with the Jurkat cell line in these experiments. Since the experimental system is based on the use of an allogeneic cell line, we expect multiple antigens, encoded by a broad array of polymorphisms, including other HLA alleles to be involved. We have therefore taken advantage of the genetic differences between responding cells and the leukaemia cell line by using the combined repertoires of membrane expressed and cross presented allo-antigens as a sensitive readout for immunological response in our experiments.
We expected that the two different procedures would provide some differences in loading of HLA molecules with tumour-derived antigens and subsequently in the responding T-cell subsets. According to the current dogma, processed peptides from phagocytosed apoptotic cells would be directed to HLA class I molecules by a process known as cross-presentation and to HLA class II molecules by the classical pathway. Cross-priming of CTL with antitumor activity has been demonstrated with DCs loaded with apoptotic tumour cells [19, 21, 35]. Specifically, Schnurr et al. demonstrated the antigens from apoptotic pancreatic carcinoma cell lines, either in form of whole cells or as released particles, were potent in inducing CTL-cell priming and activation by DC. In addition, Hoffman et al. reported stronger CTL responses with apoptotic tumour cells in a squamous cell carcinoma model. The enhanced CTL activation by antigens from apoptotic cells may be attributed to several mechanisms. After ingestion, most particulated antigens requiring phagocytosis are digested into peptides associating with HLA class-II molecules in the endocytic compartments and are presented to T-helper cells . Conversely, scavenger receptor-mediated phagocytosis of apoptotic tumour cells allows antigens to gain access to HLA class-I compartments, resulting in cross-presentation of the antigens to CTL . In addition, enhanced CTL responses to tumours might be mediated by heat shock proteins expressed by stress induced apoptotic tumour cells . On the basis of this theoretical background and reported observations [21, 31] we believe that antigen preparations from apoptotic tumour cells can also represent an alternative in DC-based tumour vaccines. On the other hand, tumour mRNA expressed in DCs would be processed for presentation by HLA class I molecules. In accordance with this, DCs loaded with apoptotic leukaemia cells stimulated both CD4+ and CD8 positive T cells and mRNA loaded DCs were superior in inducing CD8+ T-cell responses [38, 39]. Interestingly, mRNA-loaded DCs were also able to induce specific CD4+ T-cell responses in all donors tested, suggesting some leakage of endogenously produced proteins into the lysosomal antigen-processing compartments. Similar results have recently been published by Su et al., who demonstrated a significant Th response against the defined tumour antigen hTERT following in vitro stimulation of un-fractionated T cells with hTERT mRNA transfected DC. The Th response could be further augmented by targeting the antigen to the lysosomal compartment using mRNA encoding a chimeric hTERT/lysosome-associated membrane protein (LAMP-1) protein.
The aim of the present study was to determine if loading of DCs with antigens derived from a tumour cell line, either as apoptotic cells or as mRNA would provide a basis for an efficient vaccine, using ELISPOT as a read-out of immune responses. It has been shown that DCs transfected with antigens encoded in tumor mRNA is capable of inducing potent T-cell responses against tumour-specific epitopes . While protein antigens from tumour lysate are rapidly proteolysed following endocytosis by antigen-presenting cells, model experiments using mRNA encoding a fluorescent protein, EGFP, has shown that protein is still being produced 24 hrs after transfection of DCs, with peak expression after 48 hrs . Thus, tumor mRNA transfected DCs may not only represent a potent strategy for CTL priming but may also represent a general method for DC-based vaccines. In vaccine preparations using DCs, mRNA is thus preferable to a protein lysate. Similarly, immunization with DCs loaded with mRNA from leukaemia cells could represent a feasible approach in treatment of these cancers. It is now widely accepted that not only CTLs but also CD4 (+) T-helper cells are critical to the generation and maintenance of potent antitumor responses in vivo. In this context, our observation and that of others demonstrating that DCs loaded with mRNA also are equally capable of inducing Th responses strongly argue in favour of this type of vaccination. Our preclinical results further support that vaccination of leukemia patients with tumour-mRNA transfected autologous DCs should be clinically evaluated as therapeutic strategy.
- Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G, Janka-Schaub GE, Kamps W, Masera G, Sallan S, Tsuchida M, Vilmer E: Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000, 14: 2193-2194. 10.1038/sj.leu.2401977.View ArticlePubMedGoogle Scholar
- Lie SO, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Gustafsson G: A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol. 1996, 94: 82-88. 10.1046/j.1365-2141.1996.d01-1761.x.View ArticlePubMedGoogle Scholar
- Pui CH, Campana D, Evans WE: Childhood acute lymphoblastic leukaemia – current status and future perspectives. Lancet Oncol. 2001, 2: 597-607. 10.1016/S1470-2045(01)00516-2.View ArticlePubMedGoogle Scholar
- Gustafsson G, Kreuger A, Clausen N, Garwicz S, Kristinsson J, Lie SO, Moe PJ, Perkkio M, Yssing M, Saarinen-Pihkala UM: Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr. 1998, 87: 1151-1161. 10.1080/080352598750031149.View ArticlePubMedGoogle Scholar
- Buchler T, Michalek J, Kovarova L, Musilova R, Hajek R: Dendritic cell-based immunotherapy for the treatment of hematological malignancies. Hematology. 2003, 8: 97-104. 10.1080/1024533031000084204.View ArticlePubMedGoogle Scholar
- Robson NC, Beacock-Sharp H, Donachie AM, Mowat AM: Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading. Immunology. 2003, 109: 374-383. 10.1046/j.1365-2567.2003.01664.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Banchereau J, Pascual V, Palucka AK: Autoimmunity through cytokine-induced dendritic cell activation. Immunity. 2004, 20: 539-550. 10.1016/S1074-7613(04)00108-6.View ArticlePubMedGoogle Scholar
- Hart DN: Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997, 90: 3245-3287.PubMedGoogle Scholar
- Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature. 1998, 392: 245-252. 10.1038/32588.View ArticlePubMedGoogle Scholar
- Cella M, Sallusto F, Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 1997, 9: 10-16. 10.1016/S0952-7915(97)80153-7.View ArticlePubMedGoogle Scholar
- Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med. 1996, 183: 283-287. 10.1084/jem.183.1.283.View ArticlePubMedGoogle Scholar
- Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol. 1996, 156: 2918-2926.PubMedGoogle Scholar
- Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996, 183: 87-97. 10.1084/jem.183.1.87.View ArticlePubMedGoogle Scholar
- Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996, 2: 52-58. 10.1038/nm0196-52.View ArticlePubMedGoogle Scholar
- Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 1996, 29: 371-380.View ArticlePubMedGoogle Scholar
- Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998, 4: 328-332. 10.1038/nm0398-328.View ArticlePubMedGoogle Scholar
- Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ: Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001, 61: 8513-8519.PubMedGoogle Scholar
- Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999, 190: 1669-1678. 10.1084/jem.190.11.1669.View ArticlePubMedPubMed CentralGoogle Scholar
- Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini JC, Banchereau J, Palucka AK: Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med. 2000, 192: 1535-1544. 10.1084/jem.192.11.1535.View ArticlePubMedPubMed CentralGoogle Scholar
- Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998, 392: 86-89. 10.1038/32183.View ArticlePubMedGoogle Scholar
- Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL: Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 2000, 60: 3542-3549.PubMedGoogle Scholar
- Saeboe-Larssen S, Fossberg E, Gaudernack G: mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods. 2002, 259: 191-203. 10.1016/S0022-1759(01)00506-3.View ArticlePubMedGoogle Scholar
- Grunebach F, Muller MR, Nencioni A, Brossart P: Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther. 2003, 10: 367-374. 10.1038/sj.gt.3301901.View ArticlePubMedGoogle Scholar
- Ueno H, Tcherepanova I, Reygrobellet O, Laughner E, Ventura C, Palucka AK, Banchereau J: Dendritic cell subsets generated from CD34+ hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses. J Immunol Methods. 2004, 285: 171-180. 10.1016/j.jim.2003.11.012.View ArticlePubMedGoogle Scholar
- Anichini A, Vegetti C, Mortarini R: The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother. 2004, 53: 855-864. 10.1007/s00262-004-0526-8.View ArticlePubMedGoogle Scholar
- Abraham RT, Weiss A: Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol. 2004, 4: 301-308. 10.1038/nri1330.View ArticlePubMedGoogle Scholar
- Herr W, Schneider J, Lohse AW, Meyer zum Buschenfelde KH, Wolfel T: Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods. 1996, 191: 131-142. 10.1016/0022-1759(96)00007-5.View ArticlePubMedGoogle Scholar
- Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat Med. 2004, 10: 475-480. 10.1038/nm1039.View ArticlePubMedGoogle Scholar
- Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N: Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med. 2000, 191: 423-434. 10.1084/jem.191.3.423.View ArticlePubMedPubMed CentralGoogle Scholar
- Fields RC, Shimizu K, Mule JJ: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A. 1998, 95: 9482-9487. 10.1073/pnas.95.16.9482.View ArticlePubMedPubMed CentralGoogle Scholar
- Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M, Robe J, Endres S, Eigler A: Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res. 2002, 62: 2347-2352.PubMedGoogle Scholar
- Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J: Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer. 2001, 93: 539-548. 10.1002/ijc.1365.View ArticlePubMedGoogle Scholar
- Somersan S, Larsson M, Fonteneau JF, Basu S, Srivastava P, Bhardwaj N: Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol. 2001, 167: 4844-4852.View ArticlePubMedGoogle Scholar
- Paczesny S, Beranger S, Salzmann JL, Klatzmann D, Colombo BM: Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells. Cancer Res. 2001, 61: 2386-2389.PubMedGoogle Scholar
- Shaif-Muthana M, McIntyre C, Sisley K, Rennie I, Murray A: Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res. 2000, 60: 6441-6447.PubMedGoogle Scholar
- Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C, Germain RN, Mellman I, Steinman RM: The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med. 2000, 191: 927-936. 10.1084/jem.191.6.927.View ArticlePubMedPubMed CentralGoogle Scholar
- Feng H, Zeng Y, Whitesell L, Katsanis E: Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood. 2001, 97: 3505-3512. 10.1182/blood.V97.11.3505.View ArticlePubMedGoogle Scholar
- Muller MR, Grunebach F, Nencioni A, Brossart P: Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol. 2003, 170: 5892-5896.View ArticlePubMedGoogle Scholar
- Muller MR, Tsakou G, Grunebach F, Schmidt SM, Brossart P: Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood. 2004, 103: 1763-1769. 10.1182/blood-2003-06-2097.View ArticlePubMedGoogle Scholar
- Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med. 1997, 186: 1177-1182. 10.1084/jem.186.7.1177.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/5/20/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.